Levant Pulse Pharmaceutical Import Profile — Lebanon (DGFT 2022–2026)

Name: Levant Pulse Pharmaceutical Import Records from India — 2 Products, $533.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Levant Pulse — Pharmaceutical Importer Profile (2026) | 2 Products, $533.2K Trade | TransData Nexus

Levant Pulse

Pharmaceutical Importer · Lebanon · Advanced Oncology Focus · $533.2K Total Trade · DGFT Verified

Levant Pulse is a pharmaceutical importer based in Lebanon with a total trade value of $533.2K across 2 products in 1 therapeutic categories. Based on 13 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Levant Pulse sources from 2 verified Indian suppliers, with Reliance Life Sciences Private Limited accounting for 98.3% of imports.

Levant Pulse — Import Portfolio & Supplier Network

Levant Pulse import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Levant Pulse?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Reliance Life Sciences Private Limited	$453.2K	20	98.3%
Medicamen Biotech Limited	$7.9K	1	1.7%

Levant Pulse sources from 2 verified Indian suppliers across .

What Formulations Does Levant Pulse Import?

Formulation	Value	Ships
Rituxirel 500 MG rituximab 500 MG/50 ML	$57.8K	2
Bevacirel 400 MG bevacizumab 400MG / 16ML	$53.4K	2
Trasturel 440 MG trastuzumab for injection 440 MG	$50.0K	1
Trasturel 440 MG(trastuzumab for injection 440 MG)(trasturel 440 MG vial 2?c to8?c)	$50.0K	1
Adalirel 40MG(adalirel 40 MG 1pfs 2?c to8?c)(adalimumab 40MG/0.8ML)	$50.0K	1
Bevacirel 400MG bevacizumab 400MG / 16ML	$50.0K	1
Rituxirel 100 MG rituximab 100 MG/10 ML	$38.3K	1
Bevacirel 100 MG bevacizumab 100MG / 4ML	$33.4K	1
Bevacirel 100MG bevacizumab 100MG / 4ML	$20.2K	1
Bevacizumab 400MG/16ML (bevacirel 400MG)	$16.0K	1
Trastuzumab for injection 440 MG (trasturel 440 MG)	$12.5K	1
Rituximab 500MG/50ML (rituxirel 500MG)	$8.9K	1
Palbociclib capsules 125 MG (palbomed) mfg dt 02624002 mfg dt. 02/24 exp dt.	$7.9K	1
Rituximab 100MG/10ML (rituxirel 100MG)	$5.3K	1
Bevacizumab 100MG/4ML (bevacirel 100MG)	$4.2K	1

Levant Pulse imports 19 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bevacizumab	Advanced Oncology	$339.2K	7	0.7%	11
2	Rituximab	Advanced Oncology	$193.9K	6	1.0%	11

Levant Pulse imports 2 pharmaceutical products across 1 categories into Lebanon totaling $533.2K.

Levant Pulse — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Levant Pulse is a pharmaceutical importer and buyer based in Beirut, Lebanon. The company specializes in sourcing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. With a total import value of $533,000 USD across 13 shipments from 2022 to 2026, Levant Pulse focuses on advanced oncology treatments, importing two main products: Bevacizumab and Rituximab. The company operates from Chiah, Hazmieh Blvd., Kesrouani Building, 3rd Floor, Beirut, Lebanon. While specific details about its parent company are not publicly available, Levant Pulse plays a significant role in Lebanon's pharmaceutical distribution network, particularly in the oncology sector.

2Distribution Network

Levant Pulse's distribution network is centered in Beirut, Lebanon, where it manages the importation and distribution of pharmaceutical products. The company collaborates with Indian suppliers, notably Reliance Life Sciences Private Limited and Medicamen Biotech Limited, to source its products. While specific warehouse locations and logistics capabilities are not detailed in the available data, Levant Pulse's operations suggest a focus on efficient distribution within Lebanon, particularly in urban centers like Beirut.

3Industry Role

In Lebanon's pharmaceutical supply chain, Levant Pulse functions primarily as a pharmaceutical importer and buyer, specializing in sourcing finished pharmaceutical formulations from India. The company's focus on advanced oncology treatments indicates a strategic position in addressing the country's healthcare needs in this therapeutic area. By importing specific oncology drugs, Levant Pulse contributes to the availability of specialized medications in Lebanon, serving a niche yet critical segment of the market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Levant Pulse

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Levant Pulse's sourcing strategy exhibits a high degree of concentration, with 98.3% of its imports from India supplied by Reliance Life Sciences Private Limited. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or geopolitical issues affecting trade relations. However, the company's choice to concentrate sourcing from a single supplier may also reflect a strategic decision to ensure consistency in product quality and pricing. The stability of this relationship is crucial; any changes in the supplier's operations or policies could significantly impact Levant Pulse's ability to meet market demand.

2Supply Chain Resilience

Levant Pulse's supply chain resilience appears limited due to its heavy reliance on a single supplier, Reliance Life Sciences Private Limited, for the majority of its imports. The lack of backup suppliers increases vulnerability to potential disruptions. Additionally, the company's focus on a narrow range of formulations—19 unique products—suggests limited diversification in its product offerings. This lack of diversification may further expose Levant Pulse to risks associated with changes in supplier capabilities or market dynamics. Ensuring regulatory compliance of key suppliers is essential to maintain the quality and legality of imported products.

Importing Pharmaceuticals into Lebanon — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Lebanon

1Regulatory Authority & Framework

In Lebanon, the Ministry of Public Health (MoPH) serves as the primary regulatory authority overseeing the pharmaceutical sector. The MoPH is responsible for the registration, importation, and distribution of pharmaceutical products, ensuring they meet national standards for safety, efficacy, and quality. Key legislation governing pharmaceutical imports includes Law No. 367 of 1994, which outlines the practice of pharmacy, and its amendments, which regulate the importation and distribution of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining approval from the MoPH, which requires comprehensive documentation demonstrating the product's compliance with Lebanese regulations.

2Import Licensing & GMP

Importers of pharmaceutical products in Lebanon must obtain a license from the Ministry of Public Health, signifying that they have met all necessary requirements and are authorized to distribute pharmaceuticals in the country. Additionally, imported pharmaceutical products must be registered with the MoPH before they can be distributed. Lebanon recognizes Good Manufacturing Practice (GMP) certificates from reputable international standards, including EU GMP, WHO GMP, and PIC/S. Importers are required to ensure that their suppliers hold valid GMP certifications to guarantee product quality and safety.

Levant Pulse — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Levant Pulse's focus on advanced oncology treatments, specifically Bevacizumab and Rituximab, aligns with the growing demand for specialized cancer therapies in Lebanon. The importation of these products addresses critical healthcare needs, providing patients with access to essential medications that may not be readily available locally. This strategic focus allows Levant Pulse to cater to a niche market segment, potentially establishing itself as a key player in the oncology pharmaceutical sector within Lebanon.

2Sourcing Profile

Levant Pulse's sourcing strategy is centered on importing generic drugs from India, with a particular emphasis on oncology treatments. The company's preference for finished pharmaceutical formulations indicates a focus on ready-to-use products that meet Lebanese regulatory standards. India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for Levant Pulse's procurement needs.

3Market Positioning

Levant Pulse serves the Lebanese market by importing specialized oncology medications, positioning itself as a supplier to hospitals and healthcare providers requiring advanced cancer therapies. The company's focus on finished formulations suggests a role in wholesale distribution, ensuring that these critical medications are available to meet the needs of patients and healthcare institutions across Lebanon.

Seller's Guide — How to Become a Supplier to Levant Pulse

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Levant Pulse, given the company's focus on advanced oncology treatments and its established import channels. Potential gaps in Levant Pulse's current sourcing include the need for additional suppliers to diversify its product portfolio and mitigate risks associated with single-source dependency. Indian exporters can explore partnerships with Levant Pulse to supply a broader range of oncology medications, enhancing the availability of these treatments in the Lebanese market.

2Requirements & Qualifications

Indian exporters seeking to supply Levant Pulse and the Lebanese market must ensure that their products are registered with the Ministry of Public Health in Lebanon and comply with Lebanese regulations. Obtaining GMP certifications recognized by international standards, such as EU GMP, WHO GMP, or PIC/S, is essential to meet quality expectations. Additionally, products must adhere to Lebanese labeling requirements, including Arabic language labeling and necessary product information.

3How to Approach

Frequently Asked Questions — Levant Pulse

What products does Levant Pulse import from India?

Levant Pulse imports 2 pharmaceutical products across 1 categories. Top imports: Bevacizumab ($339.2K), Rituximab ($193.9K).

Who supplies pharmaceuticals to Levant Pulse from India?

Levant Pulse sources from 2 verified Indian suppliers. The primary supplier is Reliance Life Sciences Private Limited (98.3% of imports, $453.2K).

What is Levant Pulse's total pharmaceutical import value?

Levant Pulse's total pharmaceutical import value from India is $533.2K, based on 13 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Levant Pulse focus on?

Levant Pulse imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full Levant Pulse Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.